These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 4924221)

  • 1. [Inhibition of growth and dissolution of crystalline drugs].
    Tawashi R; Piccolo J
    Pharm Acta Helv; 1970 Nov; 45(11):653-77. PubMed ID: 4924221
    [No Abstract]   [Full Text] [Related]  

  • 2. [Technological methods for improving the solubility and increasing the dissolution rate of slightly soluble drugs (author's transl)].
    Krowczynski L
    Pharmazie; 1982 Jan; 37(1):79-83. PubMed ID: 7071117
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibited dissolution of drug crystals by certified water soluble dyes in micellar bile acid solutions.
    Dubois S; Tawashi R
    Pharm Acta Helv; 1975; 50(6):184-7. PubMed ID: 1178717
    [No Abstract]   [Full Text] [Related]  

  • 4. [Significance of the pertinent crystalline condition for the sorptive inhibition of the solution process].
    Hüttenrauch R; Keiner I
    Pharmazie; 1977 Jun; 32(6):354-5. PubMed ID: 896941
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of tetracycline base crystallization on the conditions properties of the powders and drug forms obtained. The development of directed crystallization procedures for tetracycline base].
    Lin'kov GI; Zhukovskaia SA
    Antibiotiki; 1977 Aug; 22(8):678-83. PubMed ID: 20834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A model of dissolution-controlled solute release from porous drug delivery polymeric systems.
    Peppas NA
    J Biomed Mater Res; 1983 Nov; 17(6):1079-87. PubMed ID: 6654927
    [No Abstract]   [Full Text] [Related]  

  • 7. [Amelioration and normalization of the rapidity of dissolution by microcrystallization: application to methylprednisolone].
    Moran I; Gillard J; Roland M
    J Pharm Belg; 1971; 26(2):115-34. PubMed ID: 5560483
    [No Abstract]   [Full Text] [Related]  

  • 8. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
    Blagden N; de Matas M; Gavan PT; York P
    Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Particle design of poorly water-soluble drug substances using supercritical fluid technologies.
    Yasuji T; Takeuchi H; Kawashima Y
    Adv Drug Deliv Rev; 2008 Feb; 60(3):388-98. PubMed ID: 18068261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amorphous drug nanosuspensions. 3. Particle dissolution and crystal growth.
    Lindfors L; Skantze P; Skantze U; Westergren J; Olsson U
    Langmuir; 2007 Sep; 23(19):9866-74. PubMed ID: 17696457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of aromatic hydrotropic drugs in pharmaceutical preparations by the surfactant-binding degree method.
    Pedraza A; Sicilia MD; Rubio S; Pérez-Bendito D
    Analyst; 2005 Jul; 130(7):1102-7. PubMed ID: 15965536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dissolution rate of organic pharmaceutical base materials. I].
    Reisner E; Nikolics K
    Acta Pharm Hung; 1982 Jul; 52(4):178-87. PubMed ID: 7170981
    [No Abstract]   [Full Text] [Related]  

  • 13. [Influence of adjuvants on the speed of dissolution and stability of acetylsalicylic acid in tablets. I. Effects of some disintegrating agents].
    Cid E; Jaminet F
    J Pharm Belg; 1971; 26(1):38-48. PubMed ID: 5559275
    [No Abstract]   [Full Text] [Related]  

  • 14. Solvent change co-precipitation with hydroxypropyl methylcellulose phthalate to improve dissolution characteristics of a poorly water-soluble drug.
    Sertsou G; Butler J; Hempenstall J; Rades T
    J Pharm Pharmacol; 2002 Aug; 54(8):1041-7. PubMed ID: 12195817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Stability of the principal coloring agents in tabletting. II. Effect of the active principle contained in the molecular nucleus on the stability of coloring agents].
    Delonca H; Laget JP; Saunal H; Ahmed K
    Pharm Acta Helv; 1983; 58(12):332-7. PubMed ID: 6657711
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effect of drug substances on the colloidal properties of aqueous solutions of adjuvant materials].
    Bashura GS; Pertsev IM; Bodnia VM; Pilipenko MK; Dmitrievskiĭ DI
    Farm Zh; 1975; (5):27-31. PubMed ID: 773673
    [No Abstract]   [Full Text] [Related]  

  • 17. Liquid crystals as a potential ointment vehicle.
    Wahlgren S; Lindstrom AL; Friberg SE
    J Pharm Sci; 1984 Oct; 73(10):1484-6. PubMed ID: 6502503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental determination of the diffusion boundary layer width of micron and submicron particles.
    Galli C
    Int J Pharm; 2006 Apr; 313(1-2):114-22. PubMed ID: 16529883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Polarographic determination of synthetic dyes used for the coloring of pharmaceutic preparations in Poland].
    Wójcik Z; Szyszko E
    Acta Pol Pharm; 1976; 33(2):205-9. PubMed ID: 7099
    [No Abstract]   [Full Text] [Related]  

  • 20. [Determination of interfacial energy from measures of the rats of dissolution].
    Jeannin C; Pakdee P; Carstensen JT
    Ann Pharm Fr; 1975; 33(8-9):433-40. PubMed ID: 1225123
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.